David Now Goliath? Made In China PD-1s Sought After By Multinationals
Eager For New Products As Market Evolves
From relatively little-known to high-flying, hotly pursued targets by global pharma players, Chinese domestically developed immuno-oncology drugs are ascending in both value and attractiveness, both inside China and far beyond.
You may also be interested in...
Plus deals involving WuXi AppTec/OXGENE, Oscotec/Beatica, ReViral/LianBio, Wugen/HCW Biologics, Starton/Haisco, Shanghai Junshi/AstraZeneca, HitGen/Uppthera, Bridge/LegoChem, Macrogen/Lifex, BeiGene/Boston Immune
After Novartis, US firm Coherus leaps into the China immuno-oncology fray by licensing rights to innovative drugs from Shanghai's Junshi.
Facing a slow roll-out of COVID-19 vaccines, China is implementing more promotional measures and increasing the pressure on the public to get inoculated. Vaccine diplomacy efforts meanwhile are facing challenges.